Adaptive Biotechnologies ADPT Sequencing Revenue — Number Of Revenue Performance Obligation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept adpt:NumberOfRevenuePerformanceObligation.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's sequencing revenue — number of revenue performance obligation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's sequencing revenue — number of revenue performance obligation?
- Adaptive Biotechnologies (ADPT) reported sequencing revenue — number of revenue performance obligation of 2 in Q1 2026.
- How has Adaptive Biotechnologies's sequencing revenue — number of revenue performance obligation changed year-over-year?
- Adaptive Biotechnologies's sequencing revenue — number of revenue performance obligation increased by 300.0% year-over-year, from 0.5 to 2.
- What is the long-term trend for Adaptive Biotechnologies's sequencing revenue — number of revenue performance obligation?
- Over 3 years (2022 to 2025), Adaptive Biotechnologies's sequencing revenue — number of revenue performance obligation has grown at a 0.0% compound annual growth rate (CAGR), from 2 to 2.
- What does sequencing revenue — number of revenue performance obligation mean?
- This metric represents the count of distinct promises to transfer goods or services to a customer within the sequencing revenue segment. It identifies the specific contractual obligations that must be satisfied to recognize revenue under accounting standards. Tracking this helps investors understand the complexity and structure of the company's service agreements.